Shares of HIMS experienced a dramatic drop today following the unexpected termination of its agreement with pharmaceutical giant Novo Nordisk. Investors responded negatively to the news, sending its stock price plummeting by more than 20%. The reason for the breakdown of the partnership remains unclear, but industry analysts speculate that it could